Sartorius Ventures
Otto-Brenner-Str. 20, Göttingen, Niedersachsen, 37079, Germany
Overview
Sartorius is one of the world's leading providers of laboratory and process technologies and equipment. Our innovative products and high-quality services help customers around the globe implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. Our key customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. Strongly rooted in the scientific and research communities and closely allied with customers and technology partners, the company is dedicated to its philosophy of "Turning science into solutions" every single day.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 8
Sector focus
- Biotechnology
- Health Care
- Manufacturing
- Pharmaceutical
Investment portfolio
- SPARTA Biodiscovery
Led · Equity · Oct 2023
Sparta Biodiscovery is a London-based spinout of Imperial College London that develops the Sparta single particle automated Raman trapping analysis platform for detailed physicochemical analysis of nanoparticles. The platform is designed to improve manufacturing and quality control of nanoformulations such as lipid or polymer capsules used to deliver cancer drugs and gene-therapy materials. Sparta was co-founded in 2022 by Professor Molly Stevens and CEO Dr. Jelle Penders, building on prototypes from the Stevens Group at Imperial. The company has secured up to £3.5 million in funding tied to a commercial rollout, and says the support will cover instruments, consumables and bespoke software. Sparta plans to place instruments across academic, government and commercial labs, targeting users working on gene therapy, lipid-nanoparticle cancer therapeutics and nonviral vectors. First adopters will provide feedback to support a full commercial launch in 2024.